The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial
Behrouz Kassaï(Hospices Civils de Lyon), Catherine Mercier(Centre for Interdisciplinary Research in Rehabilitation), S. Pinson(Hôpital Edouard Herriot), Valentine Bréant(Lyon 1 Université), Tiphanie Ginhoux(Lyon 1 Université), Isabelle Kemlin(Sorbonne Université), Emeline Peyric(Sorbonne Université), Vania Herbillon(Centre de Recherche en Neurosciences de Lyon), P. Combemale(Centre Léon Bérard), Diana Rodriguez(Sorbonne Université), Daniel Gérard(Lyon 1 Université), Laurence Lion‐François(Centre National de la Recherche Scientifique), François Gueyffier(Centre National de la Recherche Scientifique), Vincent des Portes(Centre National de la Recherche Scientifique), Virginie Coutinho(Sorbonne Université)
Cited by 57
Related Papers
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
|British Journal of Dermatology|2019|197
Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement
|Cytogenetics and Cell Genetics|2008|194
Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
|Journal of the European Academy of Dermatology and Venereology|2017|192
Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966
|Orphanet Journal of Rare Diseases|2020|188